Syndax Pharmaceuticals (NASDAQ:SNDX) CMO Nicholas A.J. Botwood Sells 31,235 Shares

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CMO Nicholas A.J. Botwood sold 31,235 shares of the stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $18.14, for a total value of $566,602.90. Following the transaction, the chief marketing officer owned 60,885 shares of the company’s stock, valued at approximately $1,104,453.90. This trade represents a 33.91% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Nicholas A.J. Botwood also recently made the following trade(s):

• On Thursday, June 11th, Nicholas A.J. Botwood sold 34,280 shares of Syndax Pharmaceuticals stock. The stock was sold at an average price of $18.00, for a total value of $617,040.00.

Syndax Pharmaceuticals Price Performance

SNDX stock opened at $18.25 on Friday. The stock has a 50-day moving average price of $21.06 and a two-hundred day moving average price of $21.22. The stock has a market cap of $1.62 billion, a PE ratio of -6.54 and a beta of 0.38. The company has a current ratio of 5.47, a quick ratio of 5.06 and a debt-to-equity ratio of 8.26. Syndax Pharmaceuticals, Inc. has a 1 year low of $8.59 and a 1 year high of $25.59.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its earnings results on Thursday, April 30th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.11. The firm had revenue of $64.86 million during the quarter, compared to analysts’ expectations of $69.76 million. Syndax Pharmaceuticals had a negative return on equity of 256.65% and a negative net margin of 111.88%.The company’s revenue was up 224.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.98) EPS. Equities analysts forecast that Syndax Pharmaceuticals, Inc. will post -1.66 EPS for the current fiscal year.

Hedge Funds Weigh In On Syndax Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Smartleaf Asset Management LLC grew its holdings in Syndax Pharmaceuticals by 2,698.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 2,659 shares of the company’s stock worth $55,000 after purchasing an additional 2,564 shares during the period. Larson Financial Group LLC grew its holdings in Syndax Pharmaceuticals by 192.2% during the third quarter. Larson Financial Group LLC now owns 2,922 shares of the company’s stock worth $45,000 after purchasing an additional 1,922 shares during the period. Quantbot Technologies LP bought a new position in Syndax Pharmaceuticals during the third quarter worth about $53,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in Syndax Pharmaceuticals by 26.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,223 shares of the company’s stock worth $89,000 after purchasing an additional 893 shares during the period. Finally, Lazard Asset Management LLC acquired a new position in shares of Syndax Pharmaceuticals in the second quarter valued at approximately $66,000.

Analyst Ratings Changes

Several brokerages have recently weighed in on SNDX. HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of Syndax Pharmaceuticals in a report on Friday. The Goldman Sachs Group raised their price objective on Syndax Pharmaceuticals from $28.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, April 1st. JPMorgan Chase & Co. increased their price objective on Syndax Pharmaceuticals from $33.00 to $45.00 and gave the company an “overweight” rating in a report on Monday, March 9th. Stifel Nicolaus set a $45.00 price objective on Syndax Pharmaceuticals in a report on Friday, February 27th. Finally, Wall Street Zen raised Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, March 8th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Syndax Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $42.55.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.